Bristol-Myers Squibb moves cardiac ultrasound agent closer to European market:
This article was originally published in Clinica
Bristol-Myers Squibb (BMS) has moved a major step closer to gaining European market clearance for its echocardiography contrast agent, Luminity (perflutren 150 microlitres/ml solution). The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission grant a marketing authorisation for use of the product in patients in whom non-contrast echocardiography is suboptimal and who have suspected or established coronary artery disease. The ultrasonic properties of the perflutren-containing lipid microspheres generated after activation of Luminity are very different from those of soft tissue, enhancing blood echogenicity and increasing contrast between blood and the surrounding tissues during echocardiography.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.